首页> 外文OA文献 >Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

【2h】

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

机译：II期研究评估Trifluridine / Tipiracil + Bevacizumab和Capecitabine + Bevacizumab在一线不可切入的转移性结肠直肠癌（MCRC）患者中是非有资格进行密集治疗的患者（Tasco1）：主要分析结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K. Lesniewski-Kmak; V. Moiseenko; M. Saunders; H. Wasan; G. Argiles; C. Borg; G. Creemers; M. Fedyanin; R. Glynne-Jones; P. Pfeiffer; C. Punt; D. Stroyakovskiy; A. Ten Tije; A. Van de Wouw; A. Kanehisa; R. Fougeray; N. Lopez Busto; N. Amellal; E. Van Cutsem;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
2. 3068 POSTER Capecitabine + irinotecan + bevacizumab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results [J] . S.Beslija, M.Banjin, S.Jungic, European Journal of Cancer Supplements . 2007,第4期

机译：3068 POSTER卡培他滨+伊立替康+贝伐单抗作为转移性结直肠癌（MCRC）患者（pts）的一线治疗：II期初步研究结果
3. Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer [J] . Alberto Mufioz, Carles Pericay, Carlos Garcia-Giron, Oncology Research . 2013,第4期

机译：贝伐单抗，卡培他滨和奥沙利铂的II期研究，随后贝伐单抗联合厄洛替尼作为转移性结直肠癌的一线治疗
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. Rationale and design of the TRUSTY study: a randomised multicentre open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy [O] . Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, 2018

机译：TRUSTY研究的原理和设计：三氟哌啶/替匹西酯加贝伐单抗与伊立替康氟嘧啶+贝伐单抗作为二线治疗的转移性结直肠癌患者在第一期或之后进展的随机多中心II / III期开放性研究基于奥沙利铂的化疗
7. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [O] . Daniela Bianconi, Merima Herac, Florian Posch, 2020

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果，翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab，然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

著录项

引文网络

相似文献

相关主题

期刊订阅